Floatz logo

Fepixnebart

Diabetic Peripheral Neuropathic Pain

Eli Lilly and Companymonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Diabetic Peripheral Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Duloxetine
Aga Khan University
Phase 4A
ds-5565
Bangladesh Medical University
Phase 4BBB
Duloxetine
Eli Lilly and Company
Phase 4BBB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Capsaicin
Corporacion Parc Tauli
Phase 4BBB

View all 50 →

Same molecule, other indications

Fepixnebart is also rated in:

diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
osteoarthritisDormant
B
Indicative ·
57 / 100
View asset →
osteoarthritis, kneeDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →